Aurinia Pharmaceuticals
AUPH
198 hedge funds and large institutions have $395M invested in Aurinia Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 69 increasing their positions, 49 reducing their positions, and 23 closing their positions.
66% more call options, than puts
Call options by funds: $23.6M | Put options by funds: $14.2M
41% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 49
4% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 23
0.27% more ownership
Funds ownership: 35.19% → 35.46% (+0.27%)
1% less funds holding
Funds holding: 200 → 198 (-2)
19% less capital invested
Capital invested by funds: $487M → $395M (-$92.3M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$23M |
| 2 |
AC
Armistice Capital
New York
|
+$13.3M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
+$5.87M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$4.57M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$2.91M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$8.48M |
| 2 |
Two Sigma Investments
New York
|
-$7.24M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.31M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.27M |
| 5 |
AC
Antara Capital
New York
|
-$4.89M |
AUPH Hedge Fund Activity: Q3 2023 in Review
198 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2023, worth a combined $395M — down 19% from $487M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new AUPH positions and 23 closed out — a net gain of 1 holder — while 69 added to existing stakes and 49 trimmed.
The largest buyer was Nuveen, opening a new position worth an estimated $23M. The largest seller was Renaissance Technologies, cutting an estimated $8.48M.
- 198 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2023, down from 200 in Q2 2023.
- Funds reported $395M of Aurinia Pharmaceuticals stock for Q3 2023, down 19% quarter-over-quarter.
- 24 funds opened new Aurinia Pharmaceuticals positions in Q3 2023 and 23 closed out, a net change of +1 holder.
- The largest Aurinia Pharmaceuticals buyer in Q3 2023 was Nuveen, an estimated $23M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2023 was Renaissance Technologies, an estimated $8.48M sold.
Based on aggregated 13F filings for Q3 2023.